Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Common Stock Issued
Cash raised by issuing new shares.
Journey Medical CorporationNASDAQ: DERM
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued dips below year-ago levels
Q1 FY2026 common stock issued of $220K fell 94.8% year over year, behind the +20.9% change in trailing-twelve-month common stock issued. Sequentially, it fell 95.9% from the prior quarter. Over 3 fiscal years it compounded at +392.1% a year.
Context
- Common stock issued amounted to 27.4% of revenue in FY2025, up 12.6 pp from a year earlier.
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -94.8% toward the trailing-twelve-month pace of +20.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 16.93M USD
- Year-over-year change
- +104.1%
- 4-year CAGR
- -15.1%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.93M | +104.1% |
| FY2024 | 2024-12-31 | 8.29M | +84.5% |
| FY2023 | 2023-12-31 | 4.49M | +3064.8% |
| FY2022 | 2022-12-31 | 142K | -99.6% |
| FY2021 | 2021-12-31 | 32.54M | — |
Common Stock Issued vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +20.9% is the 7th highest of 9, against a peer median of +360.6%.
- Common stock issued amounts to 20.0% of revenue for DERM, versus a peer median of 221.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $443.63M USD | +29182.4% | +196.8% | 4626.4% | |
| FY2025 | €237.74M EUR | +314.6% | +199.8% | 5303.2% | |
| LTM Mar 2026 | $77.76M USD | +406.7% | -13.1% | 237.6% | |
| LTM Mar 2026 | $43.95M USD | +43992.3% | — | 86.2% | |
| LTM Mar 2026 | $32.02M USD | +47.8% | -6.8% | 221.1% | |
| LTM Mar 2026 | €20.81M EUR | -70.1% | +334.1% | 127.5% | |
| LTM Mar 2026 | $15.81M USD | +1996.9% | — | 890.8% | |
| LTM Mar 2026 | $12.92M USD | +20.9% | +392.1% | 20.0% | |
| LTM Mar 2026 | CA$42.2K CAD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding DERM) | — | +360.6% | +196.8% | 221.1% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.42M | 4.72M |
| Deferred Income Tax | 1.57M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.47M | 4.43M | 2.61M | 6.1M | 6.29M |
| Change in Working Capital | 14.71M | 6.19M | (1.66M) | (3.77M) | (11.9M) |
| Accounts Receivables | 768K | (5.38M) | 12.55M | 4.48M | (19.34M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 21.71M | 14.34M | (18.42M) | (2.1M) | (7.27M) |
| Other Working Capital | 686K | (4.52M) | 262K | (1.92M) | 9.91M |
| Other Non-Cash Items | 20.51M | 1.12M | 4.29M | (211K) | (123K) |
| Operating Cash Flow | (2.18M) | (13.53M) | 5.24M | (9.13M) | (12.44M) |
| Capital Expenditures | (10M) | (20M) | (5M) | (15M) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10M) | (20M) | (5M) | (15M) | 0 |
| Debt Repayment | 5.05M | 16.9M | (8.95M) | 8.7M | 15.73M |
| Common Stock Issued | 32.54M | 142K | 4.49M | 8.29M | 16.93M |
| Common Stock Repurchased | 0 | (371K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.97M | (214K) | (350K) | (50K) | (16.43M) |
| Financing Cash Flow | 53.02M | 16.46M | (4.8M) | 16.99M | 16.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 40.84M | (17.08M) | (4.56M) | (7.13M) | 3.79M |
| Free Cash Flow | (12.18M) | (33.53M) | 240K | (9.13M) | (12.44M) |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.